A clinical trial of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the treatment of COVID-19 moderate hospitalized patients with severe high-risk factors
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary) ; Ritonavir+simnotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 21 Feb 2025 New trial record